Plasminogen activator
From Proteopedia
(Difference between revisions)
| Line 5: | Line 5: | ||
{{TOC limit|limit=2}} | {{TOC limit|limit=2}} | ||
| - | + | ==3D structures of plasminogen activator== | |
Updated on {{REVISIONDAY2}}-{{MONTHNAME|{{REVISIONMONTH}}}}-{{REVISIONYEAR}} | Updated on {{REVISIONDAY2}}-{{MONTHNAME|{{REVISIONMONTH}}}}-{{REVISIONYEAR}} | ||
| Line 12: | Line 12: | ||
[[1bqy]] – PLA – Pit viper | [[1bqy]] – PLA – Pit viper | ||
| - | ==Tissue plasminogen activator== | + | ===Tissue plasminogen activator=== |
[[1a5h]] – hTPA HC+LC + benzamidine – human<br /> | [[1a5h]] – hTPA HC+LC + benzamidine – human<br /> | ||
| Line 23: | Line 23: | ||
[[1tpm]], [[1tpn]] - hTPA fibrin-binding domain – NMR | [[1tpm]], [[1tpn]] - hTPA fibrin-binding domain – NMR | ||
| - | ==Urokinase-type plasminogen activator== | + | ===Urokinase-type plasminogen activator=== |
[[Urokinase]] | [[Urokinase]] | ||
[[Category:Topic Page]] | [[Category:Topic Page]] | ||
Revision as of 06:49, 20 August 2014
Plasminogen activator (PLA) is a serine protease which converts plasminogen to plasmin. It includes Tissue PLA (TPA) which is involved in breakdown of blood clots and urokinase-type PLA Urokinase. TPA structure contains heavy and light chains (HC, LC). PLA is inhibited by PLA inhibitor 1 and 2.
Contents |
3D structures of plasminogen activator
Updated on 20-August-2014
1a5i – PLA residues 213-477 + EGR-CMK – Vampire bat
1bqy – PLA – Pit viper
Tissue plasminogen activator
1a5h – hTPA HC+LC + benzamidine – human
1rtf - hTPA HC+LC
1tpg – hTPA F1-G - NMR
1bda – hTPA catalytic domain (mutant) + EGR-CMK
1pk2 – hTPA kringle 2 domain + 6-aminohexanoic acid – NMR
1tpk, 1pml - hTPA kringle 2 domain
1kdu - hTPA kringle domain – NMR
1tpm, 1tpn - hTPA fibrin-binding domain – NMR
